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Abstract 
Targeting post-translationally modified epitopes may provide a new strategy for generating 
tumor specific immune responses. Citrullination is the post-translational modification of 
arginine to citrulline catalyzed by peptidylarginine deaminase (PAD) enzymes. Presentation 
of citrullinated peptides on MHC-II has been associated with autophagy. Tumors upregulate 
autophagy and present citrullinated peptides in response to stresses including nutrient 
deprivation, oxygen deprivation, redox stress and DNA damage, making them good targets 
for immune attack. The ubiquitous glycolytic enzyme α-enolase (ENO1) is often citrullinated 
and degraded during autophagy. Immunization of mice with two citrullinated ENO1 peptides 
(ENO1 241-260cit253
 
or 11-25cit15) induced strong Th1 responses that recognize the post-
translationally modified, but not the wild type unmodified epitope. ENO1 11-25cit15 induced 
tumor therapy of melanoma cells in C57Bl/6 (B16F1 50% survival p=0.0026) and ENO1 
241-260cit253
 
in HLA-DR4 transgenic mice (B16-DR4 50% survival p=0.0048). In addition, 
ENO1 241-260cit253 induced
 
therapy of pancreatic (Pan02-DR4 50% survival p=0.0076) and 
lung (LLC/2-DR4 40% survival p=0.0142) tumors in HLA-DR4 transgenic mice. The 
unmodified epitope induced no anti-tumor response. Minimal regression of class II negative 
B16 or LLC/2 tumor was seen, confirming direct recognition of MHC-II was required. Most 
tumors only express MHC-II in the presence of IFNγ; an IFNγ inducible model showed 
strong responses, with rejection of tumors in up to 90% of animals (p=0.0001). In humans, a 
repertoire to ENO1 241-260cit253 was observed in healthy donors. This response was CD4 
mediated and seen in people with a variety of HLA types suggesting a broad application for 
this vaccine in human cancer therapy.  
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Introduction 
The challenge for cancer vaccines is to induce potent immune responses which can break 
tolerance and overcome the immunosuppressive tumor environment. One way to overcome 
immune suppression is to induce pro-inflammatory CD4 T cells. CD4 T cells are the main 
orchestrators of immune responses generating inflammatory cytotoxic cytokines such as IFNγ 
and TNFα, and chemokine gradients to promote infiltration of other immune cells including 
antigen presenting cells (APCs), macrophages and CD8 T cells.
1-4
 CD4 T cells can also 
differentiate to potent killer T cells.
5-7
 The difficulty is raising CD4 responses to tumor 
antigens which overcome self-tolerance. Recent strategies have targeted specific tumor 
mutations.
8, 9
 However, this strategy is patient specific and is hampered by the heterogeneous 
nature and ongoing adaptation of tumors.
10
 An alternative way to overcome self-tolerance is 
to target post-translational modifications. Citrullination is a post-translational modification 
which converts positively charged arginine to neutral citrulline. This process is catalyzed by a 
family of peptidylarginine deaminase (PAD) enzymes which are activated by high (mM) 
concentrations of calcium.
11
 Citrullination can occur in viable cells, either within the nucleus 
where PAD4 citrullinates regulatory proteins, or within autophagosomes where PAD2 
citrullination plays a role in protein degradation. Autophagy has also been demonstrated to be 
an efficient mechanism to enable processing of endogenous antigens for presentation on 
MHC class II molecules in professional APCs as well as epithelial cells.
11
 More recently it 
has been shown that antigen processing cells have constitutively active autophagy pathways 
and present citrullinated peptides on MHC class II to stimulate CD4 T cell responses.
12
 If 
cellular stress is accompanied by inflammation then these CD4 T cells can orchestrate the 
removal of the stressed cell.
13
 Cells undergo autophagy experiencing stresses such as nutrient 
deprivation, oxygen deprivation, redox stress and DNA damage, to promote their survival. As 
such it is unsurprising that autophagy is upregulated in rapidly proliferating tumor cells.
14
 We 
have previously shown that vaccination with citrullinated epitopes from vimentin, a protein 
involved in epithelial to mesenchymal transition (EMT), generated cytotoxic CD4 T cells that 
rapidly eliminated tumors with no associated toxicity.
15
 
 
α-enolase (ENO1) is a glycolytic enzyme catalyzing the penultimate step in glycolysis.16 
Many tumors switch to generating their energy via glycolysis even under normoxic 
conditions in a process termed the “Warburg effect”. As such ENO1 is overexpressed in a 
wide range of tumors.
17-20
 Due to its ubiquitous expression and abundance in most cells, 
ENO1 is also degraded during autophagy. Previous studies have shown that ENO1 can also 
be citrullinated.
21, 22
 Therefore, like vimentin, α-enolase may represent a good target for anti-
tumor immunity. 
 
In this study, we identified citrullinated ENO1 peptides which induce strong citrulline-
specific Th1 responses in conventional and HLA transgenic mice, and these led to an anti-
tumor effect in melanoma, pancreatic and lung cancer models. Further, a T cell repertoire to 
citrullinated ENO1 was detected in healthy human donors. Together our data shows that 
citrullinated ENO1 is a promising target for human cancer therapy. 
  
Methods 
Laboratory Practice 
These studies were conducted in a laboratory that operates under exploratory research 
principles. Standard operating procedures were used for all human and mouse T cell assays. 
These studies were performed using general research investigative assays. Procedures and 
raw data can be obtained from Scancell Limited through corresponding author and may be 
subject to non-disclosure agreements. Unless otherwise stated all reagents were obtained 
from Sigma-Aldridge.  
Cell lines and culture 
The murine melanoma B16F1 cell line (ATCC-CRL-6323), murine lung carcinoma line 
LLC/2 (ATCC-CRL-1642), murine prostate adenocarcinoma cell line TrampC1 (ATCC-
CRL-2730) and HeLa cells (ATCC-CCL-2) were obtained from the ATCC. The murine 
pancreatic cancer cell line Pan02 (CVCL_D627) was obtained from the DCTD Tumor/Cell 
line repository at the National Cancer Institute. Murine ovarian cancer cell line ID8 was 
obtained from Prof. K Roby, University of Kansas medical Centre. RTLCL Lymphoblastoid 
cell line was kindly donated by Prof. Alan Rickinson, University of Birmingham. B16F1, 
Pan02 and RTLCL cell lines were cultured in RPMI medium 1640 with L-glutamine (2 
mmol/L), and sodium bicarbonate buffered at pH 7 supplemented with 10% fetal calf serum 
(FCS). LLC/2 and ID8 cell lines were cultured in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% FCS, L-glutamine (2 mmol/L), and sodium bicarbonate 
buffered. Cell lines utilized were mycoplasma free, authenticated by suppliers (STR 
profiling), and used within ten passages. 
Plasmids and transfections 
Cell lines were transfected using the Lipofectamine Transfection Reagent (Invitrogen) 
utilizing the protocol previously described.
15
 B16F1, LLC/2 and Pan02 cells were transfected 
with constitutive HLA-DR4 using the pDC GAS chimeric HLA-DR401 plasmid. B16F1 cells 
were also transfected with the IFNγ-inducible HLA-DR4 using the pVitro 2 chimeric HLA-
DR401 plasmids where chimeric HLA-DR401 is under expression of the IFNγ-inducible 
promoter. Plasmid details have previously been described in full.
15
 
Transfected cells were selected by growth in the presence of zeocin (300 μg/mL), or 
hygromycin B (300 μg/mL). Lines were cloned by limiting dilution and expression was 
confirmed by flow cytometry using the HLA-DR PE conjugated antibody (clone L243, 
eBioscience). Cells transfected with the IFNγ-inducible plasmid were incubated overnight in 
the absence or presence of murine IFNγ (30 ng/mL, Gibco Life Technologies) before staining 
with the antibody. 
Western blotting 
Cell lysates were prepared by washing cell pellets twice with cold phosphate buffered saline 
(PBS) and lysed with radioimmunoprecipitation buffer containing protease inhibitor cocktail 
(Roche) and endonuclease at 50 U/mL (Benzonase, Millipore). Cells were kept on ice for at 
least 30 mins. Equal volumes of lysates were resolved by 4-12% denaturation SDS-PAGE gel 
(Thermofisher), 140V for 75 mins. Proteins were transferred to polyvinylidene fluoride 
transfer membrane (GE healthcare) (30V, 90 min) and blocked in 5% bovine serum albumin 
(BSA) in 0.1% PBS Tween for 1 hr. The membrane was probed with antibodies to ENO1 
(clone EPR10863(B), Abcam 1/1000) and β-actin (clone AC-15 1/2000). Proteins were 
visualized using fluorescent secondary antibodies at 1/15,000 against mouse (for ENO1) or 
rabbit (for β-actin) and a Licor detection system. Quantification was performed using Image 
Studio software and the intensity of respective bands was normalized to β-actin loading 
control. 
Peptides 
Peptides (see Table 1) were synthesized at >90% purity (Genscript), aliquoted to single use 
vials and stored lyophilized at −80°C. On the day of use they were reconstituted to the 
appropriate concentration in PBS. 
Immunization protocol 
Animal experiments were carried out with ethical approval and under Home Office approved 
project licenses. HLA-DR4 mice (Model #4149, Taconic), HLA-A2/DR1 (HHDII/DR1, 
Pasteur Institute) or C57Bl/6J mice (Charles River) aged 8-12 weeks were used. For all 
studies, mice were randomized into different groups and processed without blinding. Peptides 
were dissolved in PBS to 1 mg/mL and then emulsified with 6 μg/mouse each of CpG ODN 
1826 and MPLA (Invivogen). Peptides (25 μg/mouse) were injected subcutaneously at the 
base of the tail. Mice were immunized on day 1, 7 and 14 they were then humanely 
euthanized and their spleens removed for analysis at day 21. 
For tumor challenge experiments, mice were challenged with 2.5 × 10
4
 B16-DR4 cells, 1 × 
10
5
 Pan02-DR4 cells or 1.5 × 10
6
 LLC/2-DR4 cells subcutaneously on the right flank 3 days 
before primary immunization (unless stated otherwise) and subsequently immunized as 
above. Tumor growth was monitored at 3 to 4 day intervals and mice were humanely 
euthanized once tumor reached ≥10 mm in diameter. 
Ex vivo ELISpot assay 
ELISpot assays were performed using murine IFNγ or IL10 capture and detection reagents 
according to the manufacturer's instructions (Mabtech). In brief, the IFNγ or IL10-specific 
antibodies were coated onto wells of 96-well Immobilin-P plates. Synthetic peptides (10 
μg/mL) and 5 × 105 per well splenocytes were added to the wells in quadruplicate. Plates 
were incubated for 40 hrs at 37°C in an atmosphere of 5% CO2. After incubation, captured 
IFNγ or IL10 were detected by biotinylated specific IFNγ or IL-10 antibodies and developed 
with a streptavidin alkaline phosphatase and chromogenic substrate. Spots were analyzed and 
counted using an automated plate reader (Cellular Technologies Ltd). Lipopolysaccharide 
(LPS) at 5μg/mL was used as a positive control. For MHC blocking studies 20 μg/mL of the 
CD8 (clone 2.43), and CD4 (clone GK1.5) antibodies purchased from BioXcell were added 
to ELISpot assays. 
Granzyme B ELISA 
Supernatant from ex vivo IFNγ ELISpot assays on splenocytes were removed after 40 hrs and 
assessed for Granzyme B by ELISA assay (R&D Systems) according to manufacturer's 
instructions. 
Peripheral Blood Mononuclear Cell (PBMC) isolation 
PBMC experiments were carried out with ethical approval. Demographics of healthy donors 
are given in Table 2. Peripheral blood sample (approx. 50 mL) was drawn into lithium 
heparin tubes (Becton Dickinson). Samples were maintained at room temperature and 
processed immediately following venepuncture. PBMCs were isolated by density gradient 
centrifugation using Ficoll-Hypaque. Proliferation and cultured ELISpot assay of PBMCs 
were performed immediately after PBMC isolation. The median number of PBMCs routinely 
derived from healthy donor samples was 1.04 × 10
6
 PBMC/mL whole blood (range: 0.6 × 10
6 
- 1.48 × 10
6 
/ mL). The median viability as assessed by trypan blue exclusion was 93% (range 
90-95%).  
For CD25 depletion PBMCs were processed as above and then immediately enriched using 
anti-CD25 microbeads and MACS Cell Separation Columns (Miltenyi). 
Thymidine proliferation assay 
 PBMCs (1.5 × 10
6
 cells/well) were stimulated with individual peptides at a final 
concentration of 10 μg/mL in 2.0 mL of complete media (RPMI supplemented with L-
glutamine and penicillin/streptomycin, final concentration of 0.1 mg/mL streptomycin and 
100 units/mL penicillin, and 10 % (v/v) autologous plasma). Stimulation with purified protein 
derivative (Statens Serum Institute, final concentration 20µg/mL) and CEF, a mixture of 
peptides from cytomegalovirus, Epstein Barr and influenza viruses (Mabtech, final 
concentration of 4 µg/mL), served as positive controls. As a negative control, PBMCs were 
incubated with peptide vehicle alone. PBMCs were cultured at 37°C in 5% CO2 and 
proliferative capacity assessed at day 4, 7 and 11 post-stimulation by overnight 
3
H-thymidine 
incorporation (Perkin Elmer).  Data was expressed in terms of proliferative index (PI) defined 
as the mean peptide-specific counts per minute (cpm) divided by the mean negative control 
cpm at a given time point. A PI of >2 was defined as a positive response following 
predefined parameters. 
Proliferation/phenotyping assessed by CSFE labelling 
Freshly isolated PBMCs or CD25 depleted PBMCs were loaded with carboxyfluorescein 
succinimidyl ester (CFSE) (ThermoFisher). Briefly, a 50 µM stock solution in warm PBS 
was prepared from a master solution of 5 mM in DMSO. CFSE was rapidly added to PBMCs 
(5 × 10
6
 cells/mL loading buffer (PBS with 5% v/v heat inactivated FCS)) to achieve a final 
concentration of 5 µM. PBMCs were incubated at room temperature in the dark for 5 mins 
after which non-cellular incorporated CFSE was removed by washing twice with excess (× 
10 v/v volumes) of loading buffer (300 g x 10 mins). Cells were made up in complete media 
to 1.5 × 10
6
/mL and plated and stimulated with vehicle (negative control), PHA (positive 
control, final concentration 10 µg/mL) or peptide (10 µg/mL) as described above. 
On days 4, 7 and 10, 500 µL of cells were removed from culture, washed in PBS and stained 
with 1:50 dilution of anti-CD4 (PE-Cy5, clone RPA-T4, ThermoFisher) and anti-CD8 efluor 
450, clone RPA-T8, ThermoFisher) and anti-CD134 (PE-Cy7, Clone REA621, Miltenyi). 
Cells were washed, fixed and permeabilized using intracellular fixation/permeablization 
buffers (both ThermoFisher) according to the manufactures instructions. Intracellular staining 
for cytokines was performed using a 1:50 dilution of anti-IFNγ (clone 4S.B3, ThermoFisher) 
or anti-Granzyme B (PE, Clone GB11, Thermofisher). Stained samples were analyzed 
immediately on a MACSQuant 10 flow cytometer equipped with MACSQuant software 
version 2.8.168.16380 using stained vehicle stimulated controls to determine suitable gates. 
Human interferon-gamma (IFN) ELISpot assay 
Freshly isolated PBMCs (3 × 10
6
 cells/well in 24-well flat-bottomed plates), were stimulated 
with individual peptides at a final concentration of 10 μg/mL in 4.0 mL of complete media 
supplemented with human recombinant IL-7 (Peprotech, final concentration 20 ng/mL) and 
IL-15 (Peprotech, final concentration 10 ng/mL). PBMCs stimulated by vehicle alone served 
as a negative control. PBMCs were cultured at 37°C in an atmosphere of 5% CO2 and 
supplemented with 10 U/mL human recombinant interleukin-2 (Peprotech) after 3 days. 
Cytokine release by stimulated T cells was assessed after 13 days in an IFNγ ELISpot assay 
using capture and detection reagents according to the manufacturer’s instructions (Mabtech). 
In brief, an anti-IFNγ antibody was coated onto the wells of a 96-well Immobilin-P plate 
Millipore). Cultured PBMCs were used at 5 × 10
4 
cells/well (in quadruplicate) and stimulated 
with the relevant peptides at 10 µg/mL (200 µL final volume). Addition of vehicle or PHA 
(10 µg/mL) served as negative and positive controls respectively. Cells were incubated for 20 
hrs at 37°C in an atmosphere of 5% CO2, then captured IFNγ was detected by the addition of 
a biotinylated anti-IFNγ antibody and spots were identified with a streptavidin alkaline 
phosphatase and chromogenic substrate (BioRad). Spots were analyzed and counted using an 
automated plate reader (Cellular Technologies Ltd.) using Immunospot version 5.1.33 
software. Analysis was performed using “autocount easy blue” with an optical sensitivity of 
240, background 10, diffuse spot process 20 and min-max spot range of 0.002-8.77 mm. 
Statistical analysis 
Comparative analysis of the ELISpot results was performed by applying paired or unpaired 
ANOVA or Student t test as appropriate with values of P calculated accordingly. Comparison 
of tumor survival was assessed by log-rank test using the GraphPad Prism software version 7. 
P < 0.05 values were considered statistically significant and p < 0.01 values were considered 
highly significant. The error bars shown in the figures represent the mean and standard error 
of the mean (SEM). 
Results 
T cell responses to citrullinated ENO1 can be induced by peptide vaccination in mice. 
 
To determine if citrullinated ENO1 is a good target for anti-tumor immunity, all potential 
citrullinated epitopes were screened in transgenic HLA-DR4, HLA-DR1 and wild type 
C57Bl/6 mice for their ability to stimulate T cell responses. A panel of peptides was derived 
by dividing the human ENO1 sequence into 20 amino acid (aa) fragments which overlapped 
by 15aa. All peptides containing arginine were identified. Peptides were synthesized with the 
arginine residues replaced with citrulline and these peptides were then used to immunize 
mice (Table 1). Mice were immunized with pools of peptides covering non-overlapping 
regions of the human ENO1 sequence. Responses were then screened by IFNγ ELISpot using 
the human peptide sequences and where relevant, the corresponding murine peptide 
sequences. 
 
HLA-DR4 transgenic mice show a dominant response to a peptide spanning aa241-260 
(Figure 1A) this peptide includes a citrulline at position 253 (ENO1 241-260cit253). 
Subdominant responses to peptides spanning aa21-40, aa316-335 and aa321-340 were also 
observed. HHDII/DR1 mice show responses to aa126-145, aa316-335 and a low response to 
aa1-20 (Figure 1B). C57Bl/6 mice show responses to aa21-40, aa261-280 and aa316-335 
(Figure 1C). 
 
The screening panel used the human (Hu) ENO1 sequence, but these sequences are not 
homologous with the mouse (Mo) sequence. Therefore, cross reactivity with the murine 
epitopes was also tested. HLA-DR4 mice showed cross reactivity to murine ENO1 241-
260cit253. In HLA-DR4 mice, ENO1 21-40cit32 peptide cross reacts with the murine peptide 
but ENO1 316-335cit327 does not cross react with mouse ENO1 316-335cit327. Likewise, 
analysis of responses in C57Bl/6 and HHDII/DR1 mice show that in C57Bl/6 only the ENO1 
21-40cit32 response cross reacts with the murine homologue and none of the responses in the 
HHDII/DR1 mice cross react (Figure 1). Peptides which did not cross react were disregarded 
as these responses are probably due to the human peptide inducing foreign responses in mice 
which may not be citrulline specific and are likely to be deleted in humans. Rescreening of 
ENO1 peptides 21-40cit32, 126-145cit132 and 316-335cit327 was performed but these peptides 
gave low frequency IFNγ responses (Supplementary Figure 1). The responses to ENO1 241-
260cit253 were also rescreened in the C57Bl/6 and HHDI/DR1 mice. No significant responses 
were observed in either of these strains (Supplementary Figure 1D). 
 
In C57Bl/6 mice, immunization with the peptide ENO1 6-25cit9,15 induced no responses in 
the initial screen. However, in rheumatoid arthritis (RA) a shorter version of this peptide has 
been linked to increased binding to a number of HLA types.
22
 C57Bl/6 mice were therefore 
immunized with a shorter ENO1 11-25cit15 epitope with CpG/MPLA as an adjuvant. IFNγ 
responses to human ENO1 11-25cit15 peptide were shown and cross reacted with the mouse 
peptide (Figure 1D).  
 
The results of this screen demonstrate that citrullinated ENO1 peptides can induce IFNγ 
responses in several mouse models. Of the peptides tested Hu ENO1 241-260cit253 showed 
the highest frequency response and cross reacted with the murine peptide. Therefore, further 
studies in HLA-DR4 transgenic mice concentrated on this peptide. Studies in C57Bl/6 mice 
concentrate on the mouse ENO1 11-25cit15 peptide. 
 
Vaccination with ENO1 241-260cit253 or ENO1 11-25cit15 peptides induce citrulline 
specific Th1-type responses in HLA-DR4 transgenic and C57Bl/6 mice 
 
To further characterize the citrullinated ENO1 specific responses, mice were immunized with 
citrullinated human ENO1 peptides with CpG/MPLA as an adjuvant. IFNγ responses were 
shown to be citrulline specific and cross react specifically with the mouse citrullinated 
peptides (Figure 2A). No IL-10 responses were observed (Supplementary Figure 1E). 
 
The human ENO1 peptides are one amino acid different to the mouse peptides (Table 1) and 
may be inducing foreign responses in the murine system and thus not subject to thymic 
deletion. To prove that mice had a repertoire to the self-antigen they were also immunized 
with the murine peptides and responses were analyzed. Murine ENO1 241-260cit253 and 
ENO1 11-25cit15 peptides induced citrulline specific IFNγ immune responses (Figure 2B). 
 
To determine whether the citrullinated ENO1 peptide specific responses are CD4 mediated, 
responses were assessed in the presence of CD4 or CD8 blocking antibodies. The ENO1 241-
260cit253 response was blocked by addition of an anti-CD4 antibody (p=0.0417) but was not 
blocked by an anti-CD8 antibody (Figure 2C). This suggests that the ENO1 241-260cit253 
response is mediated by CD4 T cells. The same was true for the ENO1 11-25cit15 specific 
response in C57Bl/6 mice (Figure 2C). 
 
These results show that the citrullinated ENO1 peptides induce proinflammatory CD4-
mediated immune response in the transgenic HLA-DR4 and C57Bl/6 mouse strains. In 
addition to IFNγ we also show that the ENO1 11-25cit15 peptide induced Granzyme B to the 
citrullinated peptide but not the native sequence (Figure 2D). 
 
Vaccination against citrullinated ENO1 provides efficient tumor therapy 
 
To determine which tumor cell lines would provide potential targets for this vaccine, Western 
blots were performed for the expression of ENO1. All tumor cell lines tested showed high 
expression of ENO1 including the melanoma cell line B16, the pancreatic tumor cell line 
Pan02 and Lewis lung carcinoma cell line LLC/2 (Figure 3A). These cells are therefore good 
targets for tumor therapy studies. 
 
To determine whether immunization with citrullinated ENO1 peptides provide an anti-tumor 
effect mice were implanted subcutaneously with tumor cells at day 1 and then immunized 
with peptides in combination with CpG/MPLA on days 4, 11 and 18. Responses were 
initially tested against tumor cell lines engineered to constitutively express human HLA-DR4 
(Figure 3B-D). Mice immunized with the human ENO1 241-260cit253 peptide showed a 
significant survival advantage when compared to unimmunized mice after challenge with 
B16-DR4 (p=0.0048), LLC/2-DR4 (p=0.0142) and Pan02-DR4 (p=0.0076). To determine 
whether these responses were dependent on the tumor cells expressing HLA-DR4, responses 
were also tested in parental cell lines B16 (Figure 3E) and LLC2 (Figure 3F) with an HLA 
mismatch. In these cell lines the anti-tumor effect of immunization with ENO1 241-260cit253 
was reduced with 10% survival for B16 and no survival for LLC/2 challenged mice. This 
suggests that the CD4 T cells were partially mediating their effects by indirect tumor 
recognition but that direct recognition of the citrullinated epitopes on MHC class II on the 
tumor was more potent. 
 
Most tumors do not constitutively express MHC class II therefore the ENO1 241-260cit253 
peptide was tested in a model where HLA-DR4 was expressed under an IFNγ inducible 
promoter. We have previously shown that the levels of HLA-DR4 are similar in our inducible 
and constitutive models.
15
 In this model ENO1 241-260cit253 immunization was associated 
with 90% survival compared to no survival in the control group (Figure 4A, p<0.0001). The 
surviving mice were rechallenged with the same tumor on day 42, with no further 
immunization, to assess the formation of a memory response. Mice rejected a tumor 
rechallenge with 67% survival compared to no survival in a new control group (p=0.0112, 
Figure 4B). The anti-tumor effect of ENO1 11-25cit15 was also assessed (Figure 4C) in the 
unmodified B16 model that does not constitutively express MHC class II but can be induced 
by IFNγ. For this experiment C57Bl/6 mice were implanted with parental B16F1 on day 1 
and then immunized with human ENO1 11-25cit15 peptide on day 4, 11 and 18. Mice 
immunized with the citrullinated peptide showed a significant survival advantage (p=0.0026). 
 
To confirm that the anti-tumor effect is not dependent on using the foreign human ENO1 
peptide, mice challenged with the B16 melanoma expressing HLA-DR4 under the IFNγ 
inducible promoter were immunized with mouse ENO1 241-260cit253 or mouse ENO1 241-
260 wild type peptide with arginine at position 253 (Figure 4D). Mouse ENO1 241-260cit
241
 
peptide immunization was associated with a significant survival advantage when compared to 
the mouse ENO1 241-260 wild type immunized mice (p=0.0003) or control unimmunized 
mice (p=0.0001).  
 
These results show that the citrullinated ENO1 peptides induce anti-tumor effects against a 
number of different tumor cell lines derived from different cell types. This increase in 
survival was observed for both the human and mouse peptides and was not observed after 
immunization with the wild type peptide. 
 
A T cell repertoire to citrullinated ENO1 can be identified in humans  
 
To investigate whether a repertoire to citrullinated ENO1 241-260cit253 exists in humans, 
PBMCs were isolated from 6 healthy donors (Table 2) and cultured in the presence of human 
ENO1 241-260cit253 peptide. Thymidine proliferation assays were performed on the cells 
after 4, 7 and 11 days and the proliferation index for each was calculated (Figure 5A). 5/6 of 
the donors showed proliferation to ENO1 241-260cit253 peptide on at least one of the samples 
days. For example, Donor 1 showed a proliferative response to ENO1 241-260cit253 at day 11 
(mean 20.4) and day 7 (mean 28.6) but not at day 4 (mean 0.8). Responses to ENO1 241-260 
wild type peptides with arginine at position 253, were consistently low at day 11 (mean 0.9), 
7 (mean 1.2) and 4 (mean 0.3). In contrast, Donor 2 showed only a low-level response at day 
11 (mean 2.7) and Donor 6 was a non-responder. For each donor, HLA types were 
determined and are shown in table 2. 
 
Donor 4 showed a high proliferation index at day 4 (mean 12.5) and day 7 (mean 28) and day 
11 (4.4). This donor was chosen for further analysis. In order to determine the phenotype of 
proliferation responses, PBMCs from donor 4 were labelled with CFSE prior to ex vivo 
culture in the presence of peptides. Cells were assessed at day 10 for the phenotype of the 
proliferating population (Figure 5B). Of the proliferating CFSE low population responding to 
the citrullinated ENO1 peptide, between 73-96% of cells were CD4+ and 0-2% were CD8+. 
ENO1 241-260cit253 peptide showed increased proportions of CFSE
low
CD4+ cells compared 
to ENO1 241-260 wild type peptide. 
Although proliferation was observed in these samples the overall number of proliferating 
cells was relatively low and therefore difficult to reliably phenotype. Therefore, CFSE 
proliferation assays were also carried out on CD25 depleted PBMCs (Figure 5C). In these 
samples the number of CD4+ cells which proliferated was significantly higher. The ENO1 
241-260cit253 stimulated sample showed an increase in the proportions of CFSE
low
 CD4+ 
cells expressing the activation marker CD134 and the cytokine Granzyme B. 
 
To determine whether these responses were a Th1 phenotype PBMCs were cultured for 13 
days with ENO1 241-260cit253 or wild type peptide, restimulated with citrullinated or wild 
type ENO1 peptide and cytokine release measured by IFNγ ELISpot assay. Figure 5D shows 
results of the IFNγ ELISpot assay on donors 1 and 4. Cells from both donors show responses 
to the citrullinated peptide but not the wild type peptide. Further analysis of these responses 
by intracellular cytokine staining confirms IFNγ responses to be CD4 mediated (Figure 5E).  
 
These results suggest that healthy humans have a repertoire of CD4 T cells capable of 
responding to the ENO1 241-260cit253 peptide. This repertoire shows a citrulline specific 
proliferative response to ENO1 and the production of Th1 cytokines. Interestingly analysis of 
the HLA types of donors tested showed only one responding donor to be HLA-DR4 positive. 
This implies that citrullinated ENO1 specific responses are restricted through other HLA 
alleles. This has implications for vaccine design as it suggests the vaccine would be 
applicable to a broader population.  
Discussion 
The challenge for cancer immunotherapy is to generate immune responses that can recognize 
and destroy diverse cancer cells with minimal cross reactivity to healthy tissue. Targeting 
epitopes that are post-translationally modified under stress conditions may provide efficient 
targets for cancer vaccines.
13
 This study focused on identifying citrullinated epitopes from 
ENO1 that can be used in vaccines to induce potent CD4 T cell responses resulting in an anti-
tumor effect. As ENO1 is over-expressed by a wide range of tumors this would allow us to 
identify a vaccine with a broad application to multiple tumor types. 
 
Our results show that citrullinated ENO1 epitopes can be used to target cancer. We identified 
one ENO1 epitope corresponding to position 241-260 with a citrulline at position 253 which 
induces responses restricted via DR4 MHC-II allele. This study utilized transgenic mice 
which express human HLA-DR4 to demonstrate that immunization with ENO1 241-260cit253 
can induce CD4-mediated IFNγ responses. In vivo HLA-transgenic tumor models were used 
to demonstrate that this epitope induces rejection of a number of tumor types including 
melanoma, lung and pancreas. RA pathogenesis has been related to enhanced binding of 
citrullinated epitopes to HLA-DR4.
23
 By also showing that a citrullinated ENO1 epitope can 
stimulate Th1 responses and induce tumor survival in C57Bl/6 mice, we suggest that this 
phenomenon is not specific to the transgenic mouse models or the HLA-DR4 haplotype and 
is more broadly applicable. This is supported by our human studies, in which PBMCs from 
donors with several HLA types were shown to respond to stimulation with the ENO1 241-
260cit253 peptide. This suggests that humans have a repertoire to the same epitope that 
induced responses in the transgenic mouse model. It also implies that citrullinated peptide 
specific responses are not restricted to HLA-DR4 positive individuals since only one of five 
of the responding donors was HLA-DR4 positive. We therefore suggest that this response is 
not specific to the transgenic mouse models or HLA-DR4 positive individuals but implies 
that citrullinated peptides can bind to a range of HLA alleles. In concordance with this there 
is evidence emerging in the literature to suggest that citrullinated peptide specific responses 
can indeed be detected through other HLA alleles in humans.
24-26
 James et al. (2010), have 
previously shown RA patients could see T cell responses in vitro to the ENO1 11-25cit15 and 
in this study we also show it is a T cell epitope in C57Bl/6 mice. However, this peptide did 
not come up in our screen in HLA-DR4 transgenic mice.
27
 This could reflect the fact that the 
HLA-DR4 mice have a different repertoire or perhaps is a consequence of this peptide also 
being a B cell epitope and therefore possibly presented by B cells in the context of 
autoimmunity. In contrast ENO1 241-260cit253 was a good epitope in both the HLA-DR4 
transgenic mice and normal donors. Gersner et al. (2016), have shown that both the wild type 
and the citrullinated versions of ENO1 241-255 epitope bind equally well to HLA-DR4.
22
 
This suggests that citrulline is not always an MHC-II binding residue but can interact with the 
T cell receptor creating a neo-epitope.  
 
Anti-tumor CD4 T cells can induce anti-tumor immunity either indirectly or directly. If they 
work indirectly the anti-tumor effect would not require MHC-II expression on the tumor cells 
and as most tumor cells do not constitutively express MHC-II this could be important. CD4 T 
cells can be activated at the tumor site by APCs which have processed and presented tumor 
antigens on MHC-II. The CD4 T cells can then release cytotoxic cytokines which can have a 
cytostatic or cytotoxic effect on the tumor cells and/or can recruit other immune effectors cell 
such as CD8 T cells
1-4
. This response would work equally well on MHC mismatched tumors. 
In this study, although a small anti-tumor response was seen in the HLA-DR4 mice against 
the HLA mismatched tumor lines, the response against HLA-DR4 expressing lines was far 
superior. Although most tumors do not express MHC-II, it can be induced by IFNγ, it was 
therefore important to create a model in which MHC-II was under the control of the IFNγ 
promoter. As similar anti-tumor responses were generated in both the constitutive and 
inducible HLA-DR4 models it suggests that the potent Th1 CD4 cells can secrete sufficient 
IFNγ to induce class II expression. It also implies that the anti-tumor response was primarily 
mediated by direct CD4 tumor recognition. In this context, it is of interest that in both the 
mouse model and the human in vitro assays the CD4 T cells were expressing Granzyme B 
suggesting that they were cytotoxic CD4 T cells. Cytotoxic CD4 cells have been difficult to 
induce by vaccination but adoptively transferred naïve CD4 cells recognizing self-antigens 
have been shown to differentiate to cytotoxic CTL in lymphopenic hosts and this can be 
enhanced with OX40 engagement or following CD137/CD134 costimulation.
5-7
 It is also of 
interest that in our study these cells do not appear to be terminally differentiated as 
rechallenge of animals that had rejected their initial tumor showed a memory response that 
efficiently rejected the new tumors. 
 
As well as working as a glycolytic enzyme, ENO1 can also be expressed on the cell surface 
where it acts as a plasminogen binding receptor.
16
 Several groups have either used 
monoclonal antibodies or induced antibody responses with a DNA vaccine encoding 
unmodified ENO1, to induce anti-tumor responses.
20, 28
 The benefit of targeting citrullinated 
ENO1 has the potential to increase the specificity of the immune response generated and to 
minimize the normal tissue toxicity. In this study, we showed efficient anti-tumor responses 
against a range of tumor models and the ability to induce a memory response that rejects a 
new challenge with fresh tumor with no associated toxicity in either transgenic or normal 
mice.  
 
Citrullination can occur during cell death when osmotic control is lost and high levels of 
cytoplasmic calcium activate PAD enzymes. Citrullinated proteins are precipitated and if the 
cell death is accompanied by inflammation, they can be recognized by activated B cells. The 
B cells process and present the citrullinated proteins on MHC-II which stimulates a CD4 
response, allowing antibody subclass switching and affinity maturation. In autoimmune 
diseases such as RA, collagen II-induced arthritis, sarcoidosis, celiac disease and psoriasis, 
inflammatory cell death results in antibody responses to a wide range of citrullinated proteins 
and is known to be involved in the pathogenesis of these diseases.
29-32
 This study suggests 
that inducing CD4 responses in the absence of an antibody response, does not have 
pathogenic consequences. This needs to be carefully monitored in clinical trials and it may be 
wise to initially exclude cancer patients with autoimmunity to prevent exacerbating this 
condition. 
 
Our results identify a citrullinated ENO1 epitope which can be used to generate strong Th1 
responses that can preferentially target tumor cells. The intention is to combine this epitope 
with the previously described citrullinated vimentin epitopes
15
 to create a novel vaccine for 
rapid translation into the clinic for the treatment of solid cancers. 
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Figures and Tables 
 
Figure 1. Screening IFNγ responses to peptide pools  
Transgenic mouse strains with human DR4 (A) or DR1/HHDII (B) and parental C57Bl/6 (C 
and D) mice were used to screen IFNγ responses to peptides. Mice were immunized with 
pools of 4-6 non-overlapping human citrullinated ENO1 peptides. Ex vivo responses to 
stimulation with human and mouse (Mo) equivalent citrullinated peptides were assessed by 
IFNγ ELISpot. Media only responses were used as a negative control. For each pool n=3. 
Statistical significance of peptide compared to media responses for each pool was determined 
by ANOVA with Dunnett’s post-hoc test * p<0.05, ** p<0.01, *** p<0.001. 
 
Figure 2. Human ENO1 241-260cit253 and 11-25cit
15
 peptide induces strong IFNγ 
responses 
Transgenic HLA-DR4 or parental C57Bl/6 mice were immunized with human (Hu) ENO1 
241-260cit253 or Hu ENO1 11-25cit
15 
peptide, respectively. Ex vivo ELISpot was used to 
determine the IFNγ responses to citrullinated (cit) peptide and wild type (wt) peptides (A). 
Responses were also determined after immunization with Mouse (Mo) equivalent peptides 
(B). Further, IFNγ responses after ex vivo addition of anti-CD4 or anti-CD8 blocking 
antibodies were determined (C) and ex vivo Granzyme B production in response to peptides 
determined by ELISA (D).  
 
Figure 3. Immunization with citrullinated ENO1 peptides provides an in vivo survival 
advantage in anti-tumor studies 
ENO1 Westerns blots show ENO1 protein expression in cancer cell lines, B16F1 
(melanoma), ID8 (Ovarian cancer), TrampC1 (Prostate cancer), Pan02 (Pancreatic ductal 
adenocarcinoma), LLC/2 (Lung Carcinoma), RTLCL (Lymphoblastoid cell line) and in HeLa 
cells (A). 
HLA-DR4 mice were challenged with subcutaneous implant on HLA transgenic B16-DR4 
(B), LLC2-DR4 (C), PAN02-DR4 (D) tumor cell lines on day 1. Survival is shown for 
unimmunized control animals and animals immunized with ENO1 241-260cit253 peptide on 
day 4, 11 and 18. Mice were also challenged with parental B16F1 (E) or LLC2 (F) cell lines 
before immunization as above. 
 
Figure 4. Anti-tumor advantage of immunized mice is seen in models with IFNγ-
inducible MHC-II 
Transgenic HLA-DR4 mice were challenged with B16 tumor with IFNγ inducible DR4 (B16-
iDR4). Survival was determined after immunization with Hu ENO1 241-260cit253 on day 4, 
11 and 18 (A). Surviving mice from the immunized group were rechallenged with the same 
tumor cell line at day 42 post initial tumor implant (indicated by arrow). Survival data for 
rechallenged mice and a previous unchallenged control group are shown (B). 
C57bl/6 mice were also challenged with parental B16F1 implanted subcutaneously on day 1 
and survival was assessed in unimmunized control mice or mice immunized with ENO1 11-
25cit
15
 peptide (C). In a separate experiment, mice implanted with the B16-iDR4 cell line 
were immunized with the mouse ENO1 241-260cit253 or 241-260wt peptides (D). 
For tumor studies, each group had n=10, significant p values are shown. 
  
Figure 5. ENO1 241-260cit253 peptide induces responses in human PBMCs.  
PBMCs were isolated from 6 healthy donors and cultured with media, human ENO1 241-
260cit253 or ENO1 241-260wt peptide. Thymidine assays were performed to determine 
proliferation after 4, 7 and 11 days (A). HLA typing was performed on each donor (Table 2). 
PBMCs from donor 4 were labelled with CFSE prior to stimulation with peptides. The CD4 
and CD8 populations within the CFSE labelled cell population was assessed by flow 
cytometry at day 10 (B). CD25-depleted CFSE labelled PBMCs were stimulated with media 
or ENO1 241-260cit253 peptide and analyzed by Flow cytometry on day 10. CD4+ gated 
samples are shown with staining for activation marker CD134 and cytokine Granzyme B (C). 
PBMCs from donor 1 and 4 were cultured for 13 days in the presence of ENO1 241-260cit253 
or ENO1 241-260wt peptide. PBMCs were then restimulated overnight and IFNγ responses 
were assessed by ELISpot (D). Flow cytometry staining at day 13 showed IFNγ staining in 
combination with CD4 and CD8 populations after restimulation with media, ENO1 241-
260cit253 or ENO1 241-260wt (E).  
 
Supplementary Figure 1. Multiple citrullinated ENO1 peptides induce low level IFNγ 
responses  
HHDII/DR1 (A), DR4 (B) or C57Bl/6 (C) mice were immunized with citrullinated human 
ENO1 peptides corresponding to positions 21-4032, 126-145132 or 316-335327. Ex vivo 
ELISpot was used to determine IFNγ responses. IFNγ responses to ENO1 241-260cit253 
peptide were also determined in HHDII/DR1 and C57Bl/6 mice (D). IL-10 ELISpot 
responses were determined for DR4 mice immunized with ENO1 241-260cit253 (E). 
Responses are shown to human and mouse citrullinated peptides and their wild type 
equivalents when available. Media only responses were used as a negative control. For each 
peptide n=3. Statistical significance of responses compared to media control were determined 
by ANOVA with Dunnett’s post-hoc test * p<0.05, ** p<0.01.  
 
  
Table 1 – Peptide sequences, aa coordinates and screening pools, and murine homology 
aa 
coordinates Sequence Species 
Predicted binding 
(below 20) 
DR4 DR1 I-Ab 
1-20 MSILKIHAREIFDSRGNPTV  Hu* 14.35   
 MSILRIHAREIFDSRGNPTV Mo    
6-25 IHAREIFDSRGNPTVEVDLF  Hu*    
 IHAREIFDSRGNPTVEVDLY Mo    
11-25 IFDSRGNPTVEVDLF  Hu*    
 IFDSRGNPTVEVDLY Mo    
21-40 EVDLFTSKGLFRAAVPSGAS Hu* 15.51   
 EVDLYTAKGLFRAAVPSGAS Mo   11.10 
26-45 TSKGLFRAAVPSGASTGIYE Hu* 2.16 3.02  
 TAKGLFRAAVPSGASTGIYE Mo   0.57 
36-55 PSGASTGIYEALELRDNDKT Homo*    
46-65 ALELRDNDKTRYMGKGVSKA Hu* 19.25   
 ALELRDNDKTRFMGKGVSQA Mo   10.11 
56-75 RYMGKGVSKAVEHINKTIAP Hu*    
 RFMGKGVSQAVEHINKTIAP Mo   17.15 
121-140 AGAVEKGVPLYRHIADLAGN Homo*    
126-145 KGVPLYRHIADLAGNSEVIL Hu* 2.76 12.77  
 KGVPLYRHIADLAGNPEVIL Mo    
171-190 LPVGAANFREAMRIGAEVYH Hu*    
 LPVGASSFREAMRIGAEVYH Mo    
176-195 ANFREAMRIGAEVYHNLKNV Hu*    
 SSFREAMRIGAEVYHNLKNV Mo    
241-260 VIGMDVAASEFFRSGKYDLD Hu* 7.15   
 VIGMDVAASEFYRSGKYDLD Mo    
246-265 VAASEFFRSGKYDLDFKSPD Hu*    
 VAASEFYRSGKYDLDFKSPD Mo    
256-275 KYDLDFKSPDDPSRYISPDQ Hu*    
 KYDLDFKSPDDPSRYITPDQ Mo    
261-280 FKSPDDPSRYISPDQLADLY Hu*    
 FKSPDDPSRYITPDQLADLY Mo    
316-335 VGDDLTVTNPKRIAKAVNEK Hu* 14.07   
 VGDDLTVTNPKRIAKAASEK Mo    
321-340 TVTNPKRIAKAVNEKSCNCL Hu* 8.50   
 TVTNPKRIAKAASEKSCNCL Mo    
326-345 KRIAKAVNEKSCNCLLLKVN Hu* 4.16   
 KRIAKAASEKSCNCLLLKVN Mo    
361-380 QANGWGVMVSHRSGETEDTF Hu* 4.78 13.7  
 QSNGWGVMVSHRSGETEDTF Mo    
366-385 GVMVSHRSGETEDTFIADLV Homo*    
391-410 GQIKTGAPCRSERLAKYNQL Homo*    
396-415 GAPCRSERLAKYNQLLRIEE Hu*    
 GAPCRSERLAKYNQILRIEE Mo    
401-420 SERLAKYNQLLRIEEELGSK Hu* 6.94   
 SERLAKYNQILRIEEELGSK Mo    
406-425 KYNQLLRIEEELGSKAKFAG Hu* 14.6   
 KYNQILRIEEELGSKAKFAG Mo    
416-434 ELGSKAKFAGRNFRNPLAK Hu* 19.53   
 ELGSKAKFAGRSFRNPLAK Mo    
Arginine residues are shown in bold, non-homologous peptides are shown in italics 
Hu=human, Mo=Mouse, Homo=homologous 
*=immunizing peptides for screen 
 
Table 2 – Healthy donor details 
Donor 1 2 3 4 5 6 
Age (years) 20-40 40-60 20-40 40-60 20-40 20-40 
Sex Male Male Female Male Male Female 
Smoking 
Status 
Ex-
smoker 
Non-
smoker 
Non-
smoker 
Ex-smoker Non-
smoker 
Non-
smoker 
HLA type A2 
B7, 41 
C7, 17 
DR7, 
52a, 13 
DQ2, 3 
DP1, 4 
A3, 32 
B14, 35 
C4, 8 
DR2, 11 
DQ1, 7 
DP3, 4 
A3, 24 
B15, 27 
C2, 3 
DR4, 52a 
DQ3 
DP4, 9 
A1, 2 
B8, 44 
C5, 7 
DR3, 51a, 
15, 52a 
DQ2, 6 
DP1, 4 
A2, 29 
B44, 51 
 
DR7, 11 
DQ2, 
0301 
DP4, 5 
A2, 29 
B15, 44 
C3, 16 
DR4, 7, 
53a 
DQ2, 3 
DP2 
 
 
 






